PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24456746-5	2014	Blockade of CysLT1R by repeated treatment with montelukast (1 or 2 mg/kg, ig, 4 weeks) reduced Abeta1-42-induced CysLT1R expression and also suppressed Abeta1-42-induced increments of NF-kappaB p65, TNF-alpha, IL-1beta and caspase-3 activation, and Bcl-2 downregulation in the hippocampus and cortex.	montelukast	47-58	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	184-193	
32303879-11	2021	Montelukast mitigated THIM-induced social deficit probably through alpha7nAChRs upregulation, NF-kappaB p65, Bax, and brain injury markers downregulation, thus suppressing THIM-induced neuronal toxicity and inflammation.	montelukast	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	94-103	
32303879-13	2021	Some of these abnormalities could be ameliorated by montelukast via upregulation of alpha7nAChRs that inhibited NF-kappaB activation and significant suppression of neuronal injury and the associated apoptosis.	montelukast	52-63	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	112-121	
29268191-9	2018	Mechanistically, we found that montelukast suppressed LPS-induced nuclear translocation of NF-kappaB p65 as well as NF-kappaB transcriptional activity by inhibiting the phosphorylation and degradation of IkappaBalpha.	montelukast	31-42	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	91-100	
29268191-9	2018	Mechanistically, we found that montelukast suppressed LPS-induced nuclear translocation of NF-kappaB p65 as well as NF-kappaB transcriptional activity by inhibiting the phosphorylation and degradation of IkappaBalpha.	montelukast	31-42	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125